Camilla Djenne Buarque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Camilla Djenne Buarque has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Pierre Mothe Esteves
Instituto de Química Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil
5 shared publications - Marcelo Folhadella Martins Faria Azevedo
Department of Chemistry, Pontifical Catholic University of Rio de Janeiro (PUC-Rio), Rio de Janeiro 22451-900, Brazil
4 shared publications - Miquéias Lopes-Pacheco
Emory University School of Medicine
4 shared publications - Paulo Roberto Ribeiro Costa
Laboratório de Química Bioorgânica (LQB), Instituto de Pesquisa de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, Brazil
4 shared publications - Filipa C. Ferreira
Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal
3 shared publications - Carolina Bastos Pereira Ligiéro
Centro Brasileiro de Pesquisas Físicas 2 , Rua Dr. Xavier Sigaud, 150—Urca, 2290-180 Rio de Janeiro, RJ
2 shared publications
Latest Publications
- 4 February 2026
- Published by Elsevier in Tetrahedron
- Vol. 194
Cu(II)-mediated oxidative cyclization of azocoumarins to N2-1,2,3-chromenotriazoles: Synthesis and structural characterization
- 4 February 2026
- Published by Elsevier in Tetrahedron
- Vol. 194
Cu(II)-mediated oxidative cyclization of azocoumarins to N2-1,2,3-chromenotriazoles: Synthesis and structural characterization
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Química Nova
SÍNTESE DIDÁTICA DO IVACAFTOR: INTEGRANDO REAÇÕES-CHAVE E PRÁTICA LABORATORIAL NA FORMAÇÃO DE ESTUDANTES DE QUÍMICA
DIDACTIC SYNTHESIS OF IVACAFTOR: INTEGRATING KEY REACTIONS AND LABORATORY PRACTICE IN CHEMISTRY EDUCATION. The drug ivacaftor, one of the components of the medication Trikafta®/Kaftrio® recently incorporated into the Brazilian Unified Health System (SUS) for the treatment of cystic fibrosis, served as a model for the creation of an innovative teaching platform at PUC-Rio. The project integrated theory and practice in the teaching of organic chemistry, encouraging student autonomy and the development of critical laboratory skills within the academic schedule. The pedagogical strategy was based on the synthesis of two fundamental intermediates: ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate and 5-amino-2,4-di-tert-butylphenyl ethyl carbonate. Although the original synthetic routes described in patents served as a basis, modifications were implemented to optimize the process in a teaching environment. The final step consisted of forming the amide bond to connect the key intermediates, followed by basic hydrolysis. In the end, the synthesis of ivacaftor had an overall average yield of 40%.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Química Nova
SÍNTESE DIDÁTICA DO IVACAFTOR: INTEGRANDO REAÇÕES-CHAVE E PRÁTICA LABORATORIAL NA FORMAÇÃO DE ESTUDANTES DE QUÍMICA
DIDACTIC SYNTHESIS OF IVACAFTOR: INTEGRATING KEY REACTIONS AND LABORATORY PRACTICE IN CHEMISTRY EDUCATION. The drug ivacaftor, one of the components of the medication Trikafta®/Kaftrio® recently incorporated into the Brazilian Unified Health System (SUS) for the treatment of cystic fibrosis, served as a model for the creation of an innovative teaching platform at PUC-Rio. The project integrated theory and practice in the teaching of organic chemistry, encouraging student autonomy and the development of critical laboratory skills within the academic schedule. The pedagogical strategy was based on the synthesis of two fundamental intermediates: ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate and 5-amino-2,4-di-tert-butylphenyl ethyl carbonate. Although the original synthetic routes described in patents served as a basis, modifications were implemented to optimize the process in a teaching environment. The final step consisted of forming the amide bond to connect the key intermediates, followed by basic hydrolysis. In the end, the synthesis of ivacaftor had an overall average yield of 40%.
- 11 November 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1353
Chiral Resolution, stereochemical assignment and correction of a cystic fibrosis-causing variant of Aryl-Triazolyl-methanol derivative
- 11 November 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1353
Chiral Resolution, stereochemical assignment and correction of a cystic fibrosis-causing variant of Aryl-Triazolyl-methanol derivative
- Open Access
- 21 April 2025
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 3, 1008107
Synthesis and antitumoral activity of novel biaryl hydroxy-triazole and fluorene-triazole hybrids
Aim: The development of selective and potent antitumor agents remains a significant challenge. This study aimed to synthesize and evaluate biaryl hydroxy-1,2,3-triazoles and 9H-fluorene-1,2,3-triazole hybrids, inspired by previously identified bioactive 1,2,3-triazoles, for their cytotoxic potential against human cancer cell lines. Methods: A library of 13 biaryl hydroxy-1,2,3-triazoles and 11 fluorene-1,2,3-triazoles was synthesized using optimized Suzuki and telescopic one-pot reactions, with yields ranging from 16% to 97%. The cytotoxicity of these compounds was tested against HCT-116 (colorectal cancer), SNB-19 (astrocytoma), MDA-MB-231 (triple-negative breast cancer), and MOLM-13 (acute myeloid leukemia, FLT3-ITD mutant) cell lines. Results: Two fluorene-triazoles, 1-(2-bromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO258) and 1-(4-bromophenyl)-4-(2-fluoro-9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO272), both containing bromine substituents, exhibited selective cytotoxicity against MOLM-13, with half-maximal inhibitory concentration (IC50) values of 25.5 μM and 12.5 μM, respectively. Furthermore, LSO258 and LS0272 showed a selectivity index ≥ 2 towards the MOLM-13 cell line. Biaryl hydroxy-1,2,3-triazoles displayed broader activity, with [1,1’-biphenyl]-2-yl(1-(2,5-dibromophenyl)-1H-1,2,3-triazol-4-yl)methanol (LSO278), featuring two bromine groups, demonstrating potency across HCT-116, MDA-MB-231, and MOLM-13 (IC50: 23.4 μM, 34.3 μM, and 18.7 μM, respectively). However, structural rigidity did not consistently predict activity, as 1-(2,5-dibromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO275), a rigid fluorene-triazole, was inactive. MOLM-13 was the most sensitive cell line, with compounds such as 4-(9H-fluoren-9-yl)-1-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazole (LSO259) and (1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)(4’-fluoro-[1,1’-biphenyl]-2-yl)methanol (LSO280), achieving maximum growth inhibition (MGI > 55%) despite not reaching IC50 values. Conclusions: The results highlight the critical role of bromine substitution on the aryl azide-derived ring in modulating cytotoxic activity. The study reinforces the potential of rigid fluorene-based scaffolds as promising leads for the development of targeted therapies against FLT3-mutant leukemia, aligning with previous reports on 1,2,3-triazole hybrids antiproliferative activity in leukemia models.
- 21 April 2025
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 3, 1008107
Open AccessSynthesis and antitumoral activity of novel biaryl hydroxy-triazole and fluorene-triazole hybrids
Aim: The development of selective and potent antitumor agents remains a significant challenge. This study aimed to synthesize and evaluate biaryl hydroxy-1,2,3-triazoles and 9H-fluorene-1,2,3-triazole hybrids, inspired by previously identified bioactive 1,2,3-triazoles, for their cytotoxic potential against human cancer cell lines. Methods: A library of 13 biaryl hydroxy-1,2,3-triazoles and 11 fluorene-1,2,3-triazoles was synthesized using optimized Suzuki and telescopic one-pot reactions, with yields ranging from 16% to 97%. The cytotoxicity of these compounds was tested against HCT-116 (colorectal cancer), SNB-19 (astrocytoma), MDA-MB-231 (triple-negative breast cancer), and MOLM-13 (acute myeloid leukemia, FLT3-ITD mutant) cell lines. Results: Two fluorene-triazoles, 1-(2-bromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO258) and 1-(4-bromophenyl)-4-(2-fluoro-9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO272), both containing bromine substituents, exhibited selective cytotoxicity against MOLM-13, with half-maximal inhibitory concentration (IC50) values of 25.5 μM and 12.5 μM, respectively. Furthermore, LSO258 and LS0272 showed a selectivity index ≥ 2 towards the MOLM-13 cell line. Biaryl hydroxy-1,2,3-triazoles displayed broader activity, with [1,1’-biphenyl]-2-yl(1-(2,5-dibromophenyl)-1H-1,2,3-triazol-4-yl)methanol (LSO278), featuring two bromine groups, demonstrating potency across HCT-116, MDA-MB-231, and MOLM-13 (IC50: 23.4 μM, 34.3 μM, and 18.7 μM, respectively). However, structural rigidity did not consistently predict activity, as 1-(2,5-dibromophenyl)-4-(9H-fluoren-9-yl)-1H-1,2,3-triazole (LSO275), a rigid fluorene-triazole, was inactive. MOLM-13 was the most sensitive cell line, with compounds such as 4-(9H-fluoren-9-yl)-1-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazole (LSO259) and (1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)(4’-fluoro-[1,1’-biphenyl]-2-yl)methanol (LSO280), achieving maximum growth inhibition (MGI > 55%) despite not reaching IC50 values. Conclusions: The results highlight the critical role of bromine substitution on the aryl azide-derived ring in modulating cytotoxic activity. The study reinforces the potential of rigid fluorene-based scaffolds as promising leads for the development of targeted therapies against FLT3-mutant leukemia, aligning with previous reports on 1,2,3-triazole hybrids antiproliferative activity in leukemia models.
- 20 March 2025
- Published by Springer Nature in ChemTexts
- Vol. 11 (2) , 1-21
Arylation of C=C bonds via non-cross-coupling reactions: historical evolution of the Meerwein arylation mechanisms
- 20 March 2025
- Published by Springer Nature in ChemTexts
- Vol. 11 (2) , 1-21
Arylation of C=C bonds via non-cross-coupling reactions: historical evolution of the Meerwein arylation mechanisms
- Open Access
- 1 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 82
Rescue of Mutant CFTR Channel Activity by Investigational Co-Potentiator Therapy
Background: The potentiator VX-770 (ivacaftor) has been approved as a monotherapy for over 95 cystic fibrosis (CF)-causing variants associated with gating/conductance defects of the CF transmembrane conductance regulator (CFTR) channel. However, despite its therapeutic success, VX-770 only partially restores CFTR activity for many of these variants, indicating they may benefit from the combination of potentiators exhibiting distinct mechanisms of action (i.e., co-potentiators). We previously identified LSO-24, a hydroxy-1,2,3-triazole-based compound, as a modest potentiator of p.Arg334Trp-CFTR, a variant with a conductance defect for which no modulator therapy is currently approved. Objective/Methods: We synthesized a new set of LSO-24 structure-based compounds, screened their effects on p.Arg334Trp-CFTR activity, and assessed the additivity of hit compounds to VX-770, ABBV-974, ABBV-3067, and apigenin. After validation by electrophysiological assays, the most promising hits were also assessed in cells expressing other variants with defective gating/conductance, namely p.Pro205Ser, p.Ser549Arg, p.Gly551Asp, p.Ser945Leu, and p.Gly1349Asp. Results: We found that five compounds were able to increase p.Arg334Trp-CFTR activity with similar efficacy, but slightly greater potency promoted by LSO-150 and LSO-153 (EC50: 1.01 and 1.26 μM, respectively). These two compounds also displayed a higher rescue of p.Arg334Trp-CFTR activity in combination with VX-770, ABBV-974, and ABBV-3067, but not with apigenin. When tested in cells expressing other CFTR variants, LSO-24 and its derivative LSO-150 increased CFTR activity for the variants p.Ser549Arg, p.Gly551Asp, and p.Ser945Leu with a further effect in combination with VX-770 or ABBV-3067. No potentiator was able to rescue CFTR activity in p.Pro205Ser-expressing cells, while p.Gly1349Asp-CFTR responded to VX-770 and ABBV-3067 but not to LSO-24 or LSO-150. Conclusions: Our data suggest that these new potentiators might share a common mechanism with apigenin, which is conceivably distinct from that of VX-770 and ABBV-3067. The additive rescue of p.Arg334Trp-, p.Ser549Arg-, p.Gly551Asp-, and p.Ser945Leu-CFTR also indicates that these variants could benefit from the development of a co-potentiator therapy.
- 1 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 82
Open AccessRescue of Mutant CFTR Channel Activity by Investigational Co-Potentiator Therapy
Background: The potentiator VX-770 (ivacaftor) has been approved as a monotherapy for over 95 cystic fibrosis (CF)-causing variants associated with gating/conductance defects of the CF transmembrane conductance regulator (CFTR) channel. However, despite its therapeutic success, VX-770 only partially restores CFTR activity for many of these variants, indicating they may benefit from the combination of potentiators exhibiting distinct mechanisms of action (i.e., co-potentiators). We previously identified LSO-24, a hydroxy-1,2,3-triazole-based compound, as a modest potentiator of p.Arg334Trp-CFTR, a variant with a conductance defect for which no modulator therapy is currently approved. Objective/Methods: We synthesized a new set of LSO-24 structure-based compounds, screened their effects on p.Arg334Trp-CFTR activity, and assessed the additivity of hit compounds to VX-770, ABBV-974, ABBV-3067, and apigenin. After validation by electrophysiological assays, the most promising hits were also assessed in cells expressing other variants with defective gating/conductance, namely p.Pro205Ser, p.Ser549Arg, p.Gly551Asp, p.Ser945Leu, and p.Gly1349Asp. Results: We found that five compounds were able to increase p.Arg334Trp-CFTR activity with similar efficacy, but slightly greater potency promoted by LSO-150 and LSO-153 (EC50: 1.01 and 1.26 μM, respectively). These two compounds also displayed a higher rescue of p.Arg334Trp-CFTR activity in combination with VX-770, ABBV-974, and ABBV-3067, but not with apigenin. When tested in cells expressing other CFTR variants, LSO-24 and its derivative LSO-150 increased CFTR activity for the variants p.Ser549Arg, p.Gly551Asp, and p.Ser945Leu with a further effect in combination with VX-770 or ABBV-3067. No potentiator was able to rescue CFTR activity in p.Pro205Ser-expressing cells, while p.Gly1349Asp-CFTR responded to VX-770 and ABBV-3067 but not to LSO-24 or LSO-150. Conclusions: Our data suggest that these new potentiators might share a common mechanism with apigenin, which is conceivably distinct from that of VX-770 and ABBV-3067. The additive rescue of p.Arg334Trp-, p.Ser549Arg-, p.Gly551Asp-, and p.Ser945Leu-CFTR also indicates that these variants could benefit from the development of a co-potentiator therapy.
- 2 September 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1321
Direct access of 4-acyl-1,2,3-triazoles from acetophenones: A synthetic shortcut for novel p.Phe508del-CFTR traffic correctors
- 2 September 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1321
Direct access of 4-acyl-1,2,3-triazoles from acetophenones: A synthetic shortcut for novel p.Phe508del-CFTR traffic correctors
- 1 March 2024
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 27 (16)
Covalent Organic Frameworks as a Versatile Platform for Iron‐Catalyzed sp3 C−H Activation and Cross‐Coupling via Decarboxylative Oxidation
This work demonstrates the oxidative cross‐coupling of cinnamic acids with toluene using FeCl3 immobilized on a covalent organic framework (COF) pore wall, resulting in the synthesis of 1,3‐arylpropene derivatives. This iron‐based heterogeneous catalytic system affords the desired products in moderate yields ranging from 51 % to 65 %. Investigations using COFs with varying pore sizes indicate that larger pores facilitate the reaction, suggesting a spatial requirement for this transformation within the catalyst. The correlation between pore size and reaction efficiency provides insights into developing tailored catalysts to match the spatial requirements of the transformation. This version emphasizes the novelty of the study and the synthesis of 1,3‐arylpropene derivatives. It also clarifies that the iron‐based heterogeneous catalytic system is responsible for the reaction. Additionally, it provides a more detailed explanation of the findings regarding pore size and spatial requirements.
- 1 March 2024
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 27 (16)
Covalent Organic Frameworks as a Versatile Platform for Iron‐Catalyzed sp3 C−H Activation and Cross‐Coupling via Decarboxylative Oxidation
This work demonstrates the oxidative cross‐coupling of cinnamic acids with toluene using FeCl3 immobilized on a covalent organic framework (COF) pore wall, resulting in the synthesis of 1,3‐arylpropene derivatives. This iron‐based heterogeneous catalytic system affords the desired products in moderate yields ranging from 51 % to 65 %. Investigations using COFs with varying pore sizes indicate that larger pores facilitate the reaction, suggesting a spatial requirement for this transformation within the catalyst. The correlation between pore size and reaction efficiency provides insights into developing tailored catalysts to match the spatial requirements of the transformation. This version emphasizes the novelty of the study and the synthesis of 1,3‐arylpropene derivatives. It also clarifies that the iron‐based heterogeneous catalytic system is responsible for the reaction. Additionally, it provides a more detailed explanation of the findings regarding pore size and spatial requirements.
- Open Access
Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor
The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells. The discovery and subsequent development of CFTR modulators—small molecules acting on the basic molecular defect in CF—have revolutionized the standard of care for people with CF (PwCF), thus drastically improving their clinical features, prognosis, and quality of life. Currently, four of these drugs are approved for clinical use: potentiator ivacaftor (VX-770) alone or in combination with correctors lumacaftor, (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). Noteworthily, the triple combinatorial therapy composed of ivacaftor, tezacaftor, and elexacaftor constitutes the most effective modulator therapy nowadays for the majority of PwCF. In this review, we exploit the organic synthesis of ivacaftor, tezacaftor, and elexacaftor by providing a retrosynthetic drug analysis for these CFTR modulators. Furthermore, we describe the current understanding of the mechanisms of action (MoA’s) of these compounds by discussing several studies that report the key findings on the molecular mechanisms underlying their action on the CFTR protein.
Open AccessOrganic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor
The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells. The discovery and subsequent development of CFTR modulators—small molecules acting on the basic molecular defect in CF—have revolutionized the standard of care for people with CF (PwCF), thus drastically improving their clinical features, prognosis, and quality of life. Currently, four of these drugs are approved for clinical use: potentiator ivacaftor (VX-770) alone or in combination with correctors lumacaftor, (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). Noteworthily, the triple combinatorial therapy composed of ivacaftor, tezacaftor, and elexacaftor constitutes the most effective modulator therapy nowadays for the majority of PwCF. In this review, we exploit the organic synthesis of ivacaftor, tezacaftor, and elexacaftor by providing a retrosynthetic drug analysis for these CFTR modulators. Furthermore, we describe the current understanding of the mechanisms of action (MoA’s) of these compounds by discussing several studies that report the key findings on the molecular mechanisms underlying their action on the CFTR protein.
- 1 September 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (13) , 865-880
Antiviral Evaluation of 1,4-disubstituted-1,2,3-triazole Derivatives Against Chikungunya Virus
Aim: This work aimed to investigate the antiviral activity of two 1,4-disubstituted-1,2,3-triazole derivatives (1 and 2) against Chikungunya virus (CHIKV) replication. Materials & methods: Cytotoxi... Tweetable abstract Two 1,2,3-triazole derivatives against #Chikungunya virus showed promising antiviral activity, acting at different steps of the virus replication cycle.
- 1 September 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (13) , 865-880
Antiviral Evaluation of 1,4-disubstituted-1,2,3-triazole Derivatives Against Chikungunya Virus
Aim: This work aimed to investigate the antiviral activity of two 1,4-disubstituted-1,2,3-triazole derivatives (1 and 2) against Chikungunya virus (CHIKV) replication. Materials & methods: Cytotoxi... Tweetable abstract Two 1,2,3-triazole derivatives against #Chikungunya virus showed promising antiviral activity, acting at different steps of the virus replication cycle.